Elisabeth B Stougaard1, Peter L Kristensen2,3, Urd Kielgast4, Henrik U Andersen1, Yasmin Hamid1, Peter H Gæde5,6, Esben Søndergaard6,7, Gry H Dørflinger8,9, Karen K Fjeldborg10, Klavs W Hansen11, Henrik H Thomsen12, Thuraya M J Al-Imar13, Michael Røder14, Vikas S Sridhar15, David Cherney15, Peter Rossing1,2, Frederik Persson1. 1. 53138Steno Diabetes Center Copenhagen, Capital Region, Denmark. 2. Department of Clinical Medicine, University of Copenhagen, Capital Region, Denmark. 3. Department of Endocrinology and Nephrology, Nordsjællands Hospital, Denmark. 4. Department of Medicine, Section of Endocrinology, 60170Zealand University Hospital, Region Zealand, Denmark. 5. University of Southern Denmark, Institute for Regional Health, Odense, Denmark. 6. Steno Diabetes Center Aarhus, Aarhus University Hospital, Herlev, Denmark. 7. Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. 8. Department of Internal Medicine, DNV-Gødstrup, Central Denmark Region, Denmark. 9. Department of Clinical Medicine, University of Aarhus, Aarhus, Denmark. 10. Department of Endocrinology, Randers Hospital, Region Central Denmark, Denmark. 11. Diagnostic Centre, University Research Clinic for Innovative Patient Pathways, Silkeborg Regional Hospital, Silkeborg, Denmark. 12. Department of Internal Medicine, 53165Viborg Regional Hospital, Central Denmark Region, Denmark. 13. Steno Diabetes Center Zealand, Nykøbing Falster Hospital, Nykøbing Falster, Denmark. 14. Steno Diabetes Center Odense, University of Southern Denmark, Odense, Denmark. 15. Department of Medicine, University of Toronto, Division of Nephrology and Toronto General Hospital Research Institute, Toronto, ON, Canada.
Abstract
BACKGROUND: The indication for treatment of type 1 diabetes(T1D) with the sodium-glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin has been withdrawn in Europe likely because of concern for diabetic ketoacidosis (DKA). We calculated the incidence of DKA in people with T1D treated with SGLT2i in Denmark. METHODS: Clinical data from adults with T1D in Denmark were collected from nine outpatient clinics. Electronic health records made the search for DKA accurate. RESULTS: From a population of 10.500 we observed 134 people treated with SGLT2i over a total period of 222 patient-years. Of those 72% were female, mean age (SD) was 51.4 (13.6) years and median duration of treatment (median, IQR) with an SGLT2i were 12.0 (6.0-29.0) months. The incidence of DKA was zero%. CONCLUSION: In 134 people with T1D treated with SGLT2i we found that none of the participants developed DKA during the treatment.
BACKGROUND: The indication for treatment of type 1 diabetes(T1D) with the sodium-glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin has been withdrawn in Europe likely because of concern for diabetic ketoacidosis (DKA). We calculated the incidence of DKA in people with T1D treated with SGLT2i in Denmark. METHODS: Clinical data from adults with T1D in Denmark were collected from nine outpatient clinics. Electronic health records made the search for DKA accurate. RESULTS: From a population of 10.500 we observed 134 people treated with SGLT2i over a total period of 222 patient-years. Of those 72% were female, mean age (SD) was 51.4 (13.6) years and median duration of treatment (median, IQR) with an SGLT2i were 12.0 (6.0-29.0) months. The incidence of DKA was zero%. CONCLUSION: In 134 people with T1D treated with SGLT2i we found that none of the participants developed DKA during the treatment.
Entities:
Keywords:
Type 1 diabetes; diabetic ketoacidosis; sglt2 inhibitors
Authors: David Z I Cherney; Petter Bjornstad; Bruce A Perkins; Julio Rosenstock; Dietmar Neubacher; Jan Marquard; Nima Soleymanlou Journal: Clin J Am Soc Nephrol Date: 2021-09-17 Impact factor: 8.237
Authors: Ana Palanca; Falco van Nes; Felipe Pardo; F Javier Ampudia Blasco; Chantal Mathieu Journal: Diabetes Care Date: 2022-03-01 Impact factor: 19.112
Authors: Darren K McGuire; Weichung J Shih; Francesco Cosentino; Bernard Charbonnel; David Z I Cherney; Samuel Dagogo-Jack; Richard Pratley; Michelle Greenberg; Shuai Wang; Susan Huyck; Ira Gantz; Steven G Terra; Urszula Masiukiewicz; Christopher P Cannon Journal: JAMA Cardiol Date: 2021-02-01 Impact factor: 14.676
Authors: Daniël H van Raalte; Petter Bjornstad; Frederik Persson; David R Powell; Rita de Cassia Castro; Ping Stella Wang; Minzhi Liu; Hiddo J L Heerspink; David Cherney Journal: Diabetes Care Date: 2019-08-01 Impact factor: 19.112
Authors: Moshe Phillip; Chantal Mathieu; Marcus Lind; Eiichi Araki; Paolo di Bartolo; Richard Bergenstal; Simon Heller; Lars Hansen; Markus Florian Scheerer; Fredrik Thoren; Niki Arya; John Xu; Nayyar Iqbal; Paresh Dandona Journal: Diabetes Obes Metab Date: 2020-11-24 Impact factor: 6.577